| Nov 13 |
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
|
| Oct 30 |
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
|
| Oct 29 |
Biomea Fusion GAAP EPS of -$0.91 beats by $0.04
|
| Oct 29 |
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
|
| Oct 21 |
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
|
| Oct 15 |
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP...
|
| Oct 10 |
Morning Movers: Arcadium Lithium surges after deal to be acquired
|
| Oct 7 |
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
|
| Oct 3 |
Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
|
| Oct 1 |
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
|
